01:26 PM EST - Novamind Inc. : Announced it has been selected by Mind Medicine, Inc to host a phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults. MindMed is a clinical-stage biotech company developing the next generation of psychedelic-inspired medicines and therapies. The LSD Clinical Trial is the most advanced program in MindMed's clinical drug development pipeline and is the first commercial study of LSD in over 40 years. Novamind Inc.
shares C.NM are trading down one cent at $0.28.
